Although the arguments about access to drugs through parallel imports and compulsory-licensing agreements may have some theoretical validity, the disincentive to investment provided by such measures is massive.
The arguments that America never plays on a level field and that international trade agreements somehow undermine its national sovereignty are also subtly examined and rebutted.